Bio-Path (NASDAQ:BPTH) Rating Reiterated by HC Wainwright

Bio-Path (NASDAQ:BPTH)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a note issued to investors on Monday, BenzingaRatingsTable reports. They currently have a $25.00 target price on the stock, down from their previous target price of $28.00. HC Wainwright’s price objective would indicate a potential upside of 250.14% from the stock’s previous close.

Separately, ValuEngine raised shares of Bio-Path from a “sell” rating to a “hold” rating in a report on Tuesday, November 19th.

Shares of BPTH opened at $7.14 on Monday. The firm has a market cap of $20.91 million, a P/E ratio of -0.50 and a beta of 3.05. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.85 and a quick ratio of 13.85. Bio-Path has a 1 year low of $1.61 and a 1 year high of $73.52. The company has a 50 day simple moving average of $10.17 and a two-hundred day simple moving average of $11.98.

Hedge funds have recently made changes to their positions in the business. Morgan Stanley grew its position in shares of Bio-Path by 19,858.0% during the second quarter. Morgan Stanley now owns 19,958 shares of the company’s stock valued at $267,000 after purchasing an additional 19,858 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Bio-Path by 10.3% in the second quarter. Vanguard Group Inc. now owns 27,925 shares of the company’s stock worth $374,000 after purchasing an additional 2,601 shares during the last quarter. Finally, BlackRock Inc. increased its holdings in shares of Bio-Path by 17.5% in the second quarter. BlackRock Inc. now owns 46,879 shares of the company’s stock worth $628,000 after purchasing an additional 6,978 shares during the last quarter. Institutional investors and hedge funds own 6.13% of the company’s stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

Featured Article: Diversification in Investing

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.